Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Departments of Medicine, Institut Gustave Roussy, Paris, France.
Mathilde
M
Wagner
Benjamin
B
Besse
Corinne
C
Balleyguier
Jean-Charles
JC
Soria
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary*; D002555:Cerebrospinal Fluid / Q000166:cytology; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors